NY-CERTIK
1.12.2021 14:02:15 CET | Business Wire | Press release
CertiK , the leading global blockchain security firm headquartered in New York, today announced the completion of an $80 million Series B2 financing round. This investment is led by Sequoia, with participation from existing investors including Tiger Global, Coatue Management, and GL Ventures (Hillhouse Capital’s VC arm). This not only sets the bar for the largest single round of fundraising in the blockchain security space but now brings CertiK’s valuation to nearly $1 Billion. This is the third round of capital raised by CertiK within four months, altogether totaling just over $140M.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211201005593/en/
There has been a substantial increase in demand for blockchain security in the past few years - mostly driven by recent blockchain hacks, and stolen cryptocurrency. In 2021, $1.3 billion in cryptocurrency was lost to hacks, exploits, and scams - a large increase from the over $500 million dollars lost in 2020.
CertiK has experienced incredible growth over the past year, increasing revenues by 20x and its headcount by 4x. To date, CertiK has provided security products and services to over 1,800 clients, detected over 31,000 vulnerabilities in blockchain code, and protected over $310 billion worth of digital assets.
“Blockchain security is an indispensable link in the commercial value chain overall,” said a Sequoia spokesperson. “We are very proud to invest in CertiK, which is deeply involved in this field. This is an important addition to our global blockchain investment landscape. We believe that CertiK can create synergies with other companies we have invested in. Our goal is that Sequoia can provide CertiK with resources to jointly develop the blockchain security market.”
In addition to blockchain and smart contract auditing and formal verification through its Security Leaderboard platform, CertiK launched Skynet, the first 24/7, active-monitoring platform. Skynet monitors and protects smart contracts as well as blockchains against sophisticated security threats. As the security threat landscape continues to evolve, Skynet’s strategy is to utilize large amounts of on-chain and off-chain machine learning data. With this data Skynet can adapt and evolve, to protect smart contracts and blockchains against new threats. Both Security Leaderboard and Skynet are seeing incredible growth. Since the end of 2020, Skynet’s booked revenue has grown 2,300%, and the total number of users on the Security Leaderboard has grown 2,000%.
The newly raised capital coupled with revenue generated from both Skynet and Security Leaderboard, will be used for the development and operation of more innovative products. “Smart contract auditing and formal verification are the first steps in a blockchain security service,” CertiK Co-founder, Professor Ronghui Gu pointed out. “CertiK’s goal will be to develop more SaaS products to provide additional security benefits for clients. This includes security auditing, formal verification, monitoring, detection, as well as protection of client blockchain and smart contracts.''
CertiK strives to create a leadership team composed of the best talent. Dr. David Tarditi, who recently joined CertiK as Vice President of Engineering, has over 16 years of experience growing and leading engineering and research teams at Microsoft. He is also the inventor and co-inventor of 22 patents and has carried out research on typed intermediate languages, which gives compiler developers proof of compiler phases maintaining key correctness properties of input source code. In addition, Monier Jalal, who has over 20 years of leadership in the cybersecurity space, has also joined CertiK as Vice President of Marketing. Mr. Jalal has helped companies successfully market and launch products and has been part of the founder and executive leadership team driving the growth, acquisition, and IPO for several cybersecurity startups.
About CertiK
CertiK’s mission is to secure the cyber world. Starting with blockchain, CertiK applies cutting-edge innovations from academia into enterprise, enabling mission-critical applications to be built with security and correctness. Headquartered in New York City, CertiK was founded by computer science professors at Yale University and Columbia University. CertiK is backed by industry leaders, including Sequoia, Coatue Management, Tiger Global, GL Ventures (Hillhouse Capital’s venture arm), Binance, Coinbase Ventures, Lightspeed, and more
View source version on businesswire.com: https://www.businesswire.com/news/home/20211201005593/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 07:00:00 CEST | Press release
Galderma received a Complete Response Letter from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization Relfydess is approved in 33 markets and already launched in more than 20, including across Europe, the Middle East and Australia, with an encouraging early launch trajectory supported by positive healthcare professional feedback Regulatory filings in other territories are ongoing and remain on track Ad hoc announcement pursuant to Art. 53 LR Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufa
EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 03:45:00 CEST | Press release
EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom